Grace Therapeutics closed at $1.81 on Nov 4, down 1.63%, within 0.0% of its 52-week closing low. Volume of 64.5K shares was 0.54× its 20-day average (below normal).
Split-adjusted performance: -12.3% over one month, -23.6% over six months, -41.8% over one year.
Short interest was 1.7M shares at the Oct 15 settlement, down 2.2% from the prior report (11.2% of float, 15.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| GRCEGrace Therapeutics | $1.81 | −1.63% | −23.6% | — | — | — | $38.1M | |
| SCYXSCYNEXIS | $3.84 | −2.54% | −51.1% | −82.8% | 3147.7% | — | $38.2M | Compare |
| VERUVeru | $2.20 | +1.85% | −0.9% | — | — | — | $37.5M | Compare |
| ALDXAldeyra Therapeutics | $0.6474 | +4.32% | −62.8% | — | — | — | $39.1M | Compare |
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | Compare |
| BTMDBiote | $1.23 | +9.82% | −44.1% | −9.5% | −14.8% | 6.0 | $35.3M | Compare |
| NNVCNanoViricides | $1.38 | −3.50% | −5.5% | — | — | — | $35.2M | Compare |
| IBOImpact BioMedical | $4.10 | +1.99% | −48.8% | −57.1% | −23300.0% | 44.4 | $35.0M | Compare |
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | Compare |
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
